Oculis Holding AG (OCS)
22.65
0.01 (0.04%)
At close: Jan 22, 2025, 3:59 PM
22.69
0.18%
After-hours Jan 22, 2025, 04:00 PM EST
Company Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.
The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
The company is based in Zug, Switzerland.
Oculis Holding AG
| Country | CH |
| IPO Date | May 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Dr. Riad Sherif M.B.A., M.D. |
Contact Details
Address: Bahnhofstrasse 7 Zug, CH | |
| Website | https://oculis.com |
Stock Details
| Ticker Symbol | OCS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001953530 |
| CUSIP Number | n/a |
| ISIN Number | CH1242303498 |
| Employer ID | 00-0000000 |
| SIC Code |
Key Executives
| Name | Position |
|---|---|
| Dr. Riad Sherif M.B.A., M.D. | Chief Executive Officer & Director |
| Daniel S. Char J.D. | Chief Legal Officer |
| Gudrun Bachmann Ph.D. | Chief Technology Officer |
| Sylvia Cheung | Chief Financial Officer |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer |
| Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer |
| Dr. Snehal Shah Pharm.D. | President of Research & Development |
| Páll Ragnar Jóhannesson | Chief Business Officer |
| Rebecca Weil | Chief Commercial Officer |
| Virginia R. Dean | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 6-K | Filing |
| Jan 03, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 09, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 29, 2024 | 6-K | Filing |
| Nov 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 6-K | Filing |
| Sep 06, 2024 | 424B3 | Filing |
| Aug 27, 2024 | F-3 | Filing |
| Aug 27, 2024 | 6-K | Filing |
| Jun 10, 2024 | 6-K | Filing |